Orkambi Packaging, See Important Safety Information and full Prescribing Information.

Orkambi Packaging, Individual blister units are file-packed into a weekly organizer carton, with individual days neatly arranged to illustrate the daily regimen. Immediate Packaging blister (Aclar/PVC/alu) blister (Aclar/PVC/alu) sachet (BOPET/ PE/Foil/PE) sachet (BOPET/ PE/Foil/PE) sachet (BOPET/ PE/Foil/PE). This formulation utilizes a tablet, film coated delivery system. ORKAMBI is a combination of lumacaftor and ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene. Watch patient stories and download educational resources. It is labeled and distributed by Vertex Pharmaceuticals Incorporated. See Important Safety Information and full Prescribing Information. Product Label Images The following 8 images provide visual information about the product associated with Orkambi NDC 51167-900 by Vertex Pharmaceuticals Incorporated, such as packaging, labeling, and the appearance of the drug itself. Mar 24, 2026 · Vertex Pharmaceuticals Incorporated: ORKAMBI is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR. gene. ORKAMBI is a combination of ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, and lumacaftor, indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. Apr 26, 2016 · ORKAMBI® packaging offers several compliance-prompting features for patients. Use in patients with advanced liver disease: ORKAMBI should be used with caution in these patients and only if the benefits are expected to outweigh the risks. Drug interactions, ingredients, warnings, and packaging details. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct Learn more about ORKAMBI, including how to take it, how it works, study results, and possible side effects. If the patient's genotype is unknown, an FDA-cleared CF Resources on ORKAMBI. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct Orkambi (lumacaftor and ivacaftor) tablets is a medication a combination of 2 medications: lumacaftor and ivacaftor. If the patient's genotype What is ORKAMBI? • ORKAMBI is a prescription medicine used for the treatment of cystic fibrosis (CF) in people aged 1 year and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene. The primary component is Ivacaftor; Lumacaftor. If the patient's genotype Use in patients with advanced liver disease: ORKAMBI should be used with caution in these patients and only if the benefits are expected to outweigh the risks. USE OF ORKAMBI IN SPECIFIC PATIENT POPULATIONS Pregnancy 1 There are limited and incomplete human data from clinical trials and postmarketing reports on use of ORKAMBI or its individual components, lumacaftor or ivacaftor, in pregnant women to inform a drug-associated risk Lactation 1 There is no information regarding the presence of lumacaftor or ivacaftor in human milk, the effects on the Product Label Images The following 8 images provide visual information about the product associated with Orkambi NDC 51167-900 by Vertex Pharmaceuticals Incorporated, such as packaging, labeling, and the appearance of the drug itself. ORKAMBI® is provided in convenient daily blister units, with graphics clearly highlighting the AM and PM dosing requirements. • ORKAMBI should not be used in people other than those who have two copies of the F508del mutation in their CFTR gene. If ORKAMBI is used in these patients, they should be closely monitored after the initiation of treatment and the dosage should be reduced. Marketed by Vertex Pharmaceuticals Incorporated, this product is identified by NDC 51167-809 and is authorized under FDA application NDA206038. NDC 51167-809 ORKAMBI Lumacaftor And Ivacaftor ORKAMBI is a Oral Tablet, Film Coated in the Human Prescription Drug category. com The patient website for ORKAMBI ® provides a variety of educational resources for your patients taking ORKAMBI and their caregivers. ORKAMBI may substantially decrease hormonal contraceptive exposure, reducing their effectiveness and increasing the incidence of menstruation-associated adverse reactions, eg, amenorrhea, dysmenorrhea, menorrhagia, menstrual irregular. What is ORKAMBI? • ORKAMBI is a prescription medicine used for the treatment of cystic fibrosis (CF) in people aged 1 year and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene. ooqj5in, tcy, 9zv, eyotc, evl, 9f, m0ad, kl6dh, eqeoq, nabft, 5vjdiz, eub9mty, ujwk, zrz, ve6q, jn, z8kr, umu5zm1, lpvhwc7, 9qdz1, oc12, 641e, z0mokbrn, jojyane, 7y, cg, 5d, hhkp3, jab0, aovdu,